SMR 2019: Concurrent Intrathecal + IV Nivolumab Proves Safe in Patients With Melanoma and Leptomeningeal Metastasis
The combination was found to be feasibly administered, with no additive toxicity.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.